$DFTX News

Definium Therapeutics Announces New Employee Inducement Grants

Definium Therapeutics (DFTX) Stock May Trade Above Fair Value On Book Value

Definium Therapeutics Announces New Employee Inducement Grants

JP Morgan Initiates Coverage On Definium Therapeutics with Overweight Rating, Announces Price Target of $84

Definium Therapeutics Announces New Employee Inducement Grants

Definium Therapeutics Highlights Phase III DT120 Gains in Anxiety and Depression

Definium’s LSD Pill Clears a Second Anxiety Trial, and the Psychedelics Sector Is Watching

Definium Therapeutics’ DT120 Hits Phase III Goals in Anxiety Study

Definium Therapeutics (DFTX) Stock May Trade At A Premium Despite Phase 3 DT120 Results

Definium tees up regulatory submission for psychedelic on Phase III hat trick

Canaccord Genuity Maintains Buy on Definium Therapeutics, Raises Price Target to $78

Why Definium Therapeutics (DFTX) Is Up 5.7% After Second Positive Phase 3 DT120 Anxiety Trial Result

Baird Maintains Outperform on Definium Therapeutics, Raises Price Target to $79

Definium Therapeutics (DFTX) After Its Phase 3 Win Still Looks Undervalued

The Psychedelics News That Sent Definium, Already Up 190% This Year, Soaring

Psychedelics Are Wall Street’s Next Trip. Why This Biotech Stock Is Already Up 200%.

DFTX Stock Climbs As High As 12% On ‘Unprecedented’ Anxiety Data For LSD-Based Drug

Definium Therapeutics, Inc. (DFTX) Discusses Topline Results from Panorama Phase 3 Study of DT120 ODT in Generalized Anxiety Disorder Transcript

Definium Therapeutics, Inc. (DFTX) Discusses Topline Results from Panorama Phase 3 Study of DT120 ODT in Generalized Anxiety Disorder - Slideshow

Definium Therapeutics Shares Rise 20% After Phase 3 Anxiety Trial Meets Primary Endpoint